Crataegus - Lichtwer PharmaAlternative Names: LI 132
Latest Information Update: 09 Dec 1998
At a glance
- Originator Unknown
- Developer Lichtwer Pharma
- Class Cardiac glycosides; Cardiotonics; Heart failure therapies; Phytotherapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Heart failure